Pietro Maffei
Overview
Explore the profile of Pietro Maffei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
1978
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maffei P, Dassie F
Front Horm Res
. 2024 Nov;
55:201-214.
PMID: 39586262
Acromegaly is a chronic and progressive disorder caused by growth hormone (GH) and insulin-like growth factor 1 (IGF-1) excess, responsible for the onset of multiple systemic complications. Targets of acromegaly...
2.
Ferone D, Freda P, Katznelson L, Gatto F, Kadioglu P, Maffei P, et al.
J Clin Endocrinol Metab
. 2024 Oct;
PMID: 39378125
Context: Acromegaly, characterized by excessive growth hormone (GH) and insulin-like growth factor-1 (IGF-1), impacts quality of life (QoL) and mortality. Standard of care (SoC; octreotide long-acting repeatable or lanreotide autogel)...
3.
Abdul-Ghani M, Maffei P, DeFronzo R
Lancet Diabetes Endocrinol
. 2024 Aug;
12(9):674-680.
PMID: 39098317
Glucagon-like peptide-1 (GLP-1) receptor agonists have gained widespread use in the treatment of individuals with type 2 diabetes because of their potent weight loss promoting effect, ability to augment β-cell...
4.
Dollfus H, Lilien M, Maffei P, Verloes A, Muller J, Bacci G, et al.
Eur J Hum Genet
. 2024 Jul;
32(11):1347-1360.
PMID: 39085583
Four European Reference Networks (ERN-EYE, ERKNet, Endo-ERN, ERN-ITHACA) have teamed up to establish a consensus statement and recommendations for Bardet-Biedl syndrome (BBS). BBS is an autosomal recessive ciliopathy with at...
5.
6.
Basile M, Valentini I, Attanasio R, Cozzi R, Persichetti A, Samperi I, et al.
Glob Reg Health Technol Assess
. 2024 Jan;
11:1-16.
PMID: 38230389
Background: Prolactinoma, the most common pituitary adenoma, is usually treated with dopamine agonist (DA) therapy like cabergoline. Surgery is second-line therapy, and radiotherapy is used if surgical treatment fails or...
7.
Giampietro A, Chiloiro S, Urbani C, Pivonello R, Carlsson M, Dassie F, et al.
Endocr Connect
. 2024 Jan;
13(3).
PMID: 38197875
Purpose: The aim of this study was to examine the probability of achieving acromegaly disease control according to several patient-, disease- and treatment-related factors longitudinally. Methods: We analyzed data from...
8.
Maffei P, Bettini S, Busetto L, Dassie F
Diabetes Metab Syndr Obes
. 2023 Nov;
16:3579-3598.
PMID: 37964939
SGLT2i (sodium glucose transporter type 2 inhibitors) are pharmacological agents that act by inhibiting the SGLT2, by reducing the renal plasma glucose threshold and inducing glycosuria, resulting in a blood...
9.
Cozzi R, Auriemma R, De Menis E, Esposito F, Ferrante E, Iati G, et al.
Endocr Metab Immune Disord Drug Targets
. 2023 May;
23(12):1459-1479.
PMID: 37171003
Introduction: This guideline (GL) is aimed at providing a reference for the management of prolactin (PRL)-secreting pituitary adenoma in adults. However, pregnancy is not considered. Methods: This GL has been...
10.
Reschke F, Biester T, von dem Berge T, Jamiolkowski D, Hasse L, Dassie F, et al.
Endocr Connect
. 2023 Apr;
12(7).
PMID: 37014304
As the most visible and vulnerable organ of the human organism, the skin can provide an impression of its state of health. Rare forms of diabetes and endocrinopathies are often...